404 related articles for article (PubMed ID: 32497778)
1. A pharmacological interactome between COVID-19 patient samples and human sensory neurons reveals potential drivers of neurogenic pulmonary dysfunction.
Ray PR; Wangzhou A; Ghneim N; Yousuf MS; Paige C; Tavares-Ferreira D; Mwirigi JM; Shiers S; Sankaranarayanan I; McFarland AJ; Neerukonda SV; Davidson S; Dussor G; Burton MD; Price TJ
Brain Behav Immun; 2020 Oct; 89():559-568. PubMed ID: 32497778
[TBL] [Abstract][Full Text] [Related]
2. A pharmacological interactome between COVID-19 patient samples and human sensory neurons reveals potential drivers of neurogenic pulmonary dysfunction.
Ray PR; Wangzhou A; Ghneim N; Yousuf MS; Paige C; Tavares-Ferreira D; Mwirigi JM; Shiers S; Sankaranarayanan I; McFarland AJ; Neerukonda SV; Davidson S; Dussor G; Burton MD; Price TJ
SSRN; 2020 May; ():3581446. PubMed ID: 32714114
[TBL] [Abstract][Full Text] [Related]
3. Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
Mohammed A; F K Alghetaa H; Miranda K; Wilson K; P Singh N; Cai G; Putluri N; Nagarkatti P; Nagarkatti M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872332
[TBL] [Abstract][Full Text] [Related]
4. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
5. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
6. ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects.
Shiers S; Ray PR; Wangzhou A; Sankaranarayanan I; Tatsui CE; Rhines LD; Li Y; Uhelski ML; Dougherty PM; Price TJ
Pain; 2020 Nov; 161(11):2494-2501. PubMed ID: 32826754
[TBL] [Abstract][Full Text] [Related]
7. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications.
Pelaia C; Tinello C; Vatrella A; De Sarro G; Pelaia G
Ther Adv Respir Dis; 2020; 14():1753466620933508. PubMed ID: 32539627
[TBL] [Abstract][Full Text] [Related]
8. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
[TBL] [Abstract][Full Text] [Related]
9. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
10. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
11. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs.
Tufan A; Avanoğlu Güler A; Matucci-Cerinic M
Turk J Med Sci; 2020 Apr; 50(SI-1):620-632. PubMed ID: 32299202
[TBL] [Abstract][Full Text] [Related]
12. Type III interferons disrupt the lung epithelial barrier upon viral recognition.
Broggi A; Ghosh S; Sposito B; Spreafico R; Balzarini F; Lo Cascio A; Clementi N; De Santis M; Mancini N; Granucci F; Zanoni I
Science; 2020 Aug; 369(6504):706-712. PubMed ID: 32527925
[TBL] [Abstract][Full Text] [Related]
13. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Qin H; Zhao A
Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
16. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
Andersson U; Ottestad W; Tracey KJ
Mol Med; 2020 May; 26(1):42. PubMed ID: 32380958
[TBL] [Abstract][Full Text] [Related]
17. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
18. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.
Garvin MR; Alvarez C; Miller JI; Prates ET; Walker AM; Amos BK; Mast AE; Justice A; Aronow B; Jacobson D
Elife; 2020 Jul; 9():. PubMed ID: 32633718
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.
Xiong Y; Liu Y; Cao L; Wang D; Guo M; Jiang A; Guo D; Hu W; Yang J; Tang Z; Wu H; Lin Y; Zhang M; Zhang Q; Shi M; Liu Y; Zhou Y; Lan K; Chen Y
Emerg Microbes Infect; 2020 Dec; 9(1):761-770. PubMed ID: 32228226
[TBL] [Abstract][Full Text] [Related]
20. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.
Ahlawat S; Asha ; Sharma KK
Virus Res; 2020 Sep; 286():198103. PubMed ID: 32717345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
